Long-term follow-up of patients with hyperprolactinaemia

Clin Endocrinol (Oxf). 1996 Sep;45(3):299-303. doi: 10.1046/j.1365-2265.1996.00824.x.

Abstract

Aim: To determine the frequency with which hyperprolactinaemic illness tends to resolve with time.

Study design: A retrospective case-notes review from a specialist endocrine unit in a provincial teaching hospital and tertiary referral centre.

Patients: Seventy women with hyperprolactinaemia referred to the unit in the 15 year period between May 1979 and May 1994. All those with a non-pituitary cause or with macroadenoma had been excluded, as were those who did not have high-resolution imaging, or who were on treatment at the time of referral.

Intervention: Intermittent course of treatment with dopamine receptor agonists according to individual need.

Endpoints: Latest serum PRL concentration in those who had discontinued treatment, and whether serum PRL tended to be lower in any particular group.

Results: There was a significant fall in median PRL concentration from 2000 (714-8000) to 1000 mU/l (220-5600) in the 31 women who had discontinued therapy (P < 0.0005), and serum PRL was normal (< 700 mU/l) in 11 of them. Serum PRL also fell to normal in three of ten women who had no treatment at all. Final PRL concentration was normal in 35% of women who had had at least one pregnancy during the period of follow-up compared to 14% who had not (P < 0.05).

Conclusions: These data confirm the findings of others that hyperprolactinaemia will prove self-limiting in up to one-third of women, and that pregnancy may be one factor which triggers a return to normal function.

MeSH terms

  • Adolescent
  • Adult
  • Disease Progression
  • Dopamine Agonists / therapeutic use
  • Female
  • Follow-Up Studies
  • Humans
  • Hyperprolactinemia / drug therapy
  • Hyperprolactinemia / physiopathology*
  • Middle Aged
  • Pituitary Gland / physiopathology*
  • Pregnancy
  • Pregnancy Complications / drug therapy
  • Pregnancy Complications / physiopathology*

Substances

  • Dopamine Agonists